Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 10/20 | 0.57 |
| ▸ | ITGB7 | P26010 | 8/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21519780 | 1.00 | ITGA4 (0.57) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL21519750 | 0.99 | ITGA4 (0.58) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL21519752 | 0.99 | ITGA4 (0.58) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL30677955 | 0.93 | ITGA4 (0.49) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL21540552 | 0.93 | ITGA4 (0.49) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL21540490 | 0.92 | ITGA4 (0.49) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL21519758 | 0.90 | ITGA4 (0.60) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL4314341 | 0.90 | ITGA4 (0.60) | ITGA4ITGB7PPARAITGB3ITGA2B | |
| SCHEMBL7382968 | 0.82 | ITGA4 (0.67) | ITGA4ITGB7ACEITGB1CTSS | |
| SCHEMBL21540449 | 0.82 | ITGA4 (0.51) | ITGA4ITGB7PPARAACEPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | SAINT LOUIS UNIVERSITY | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328706-A1 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | CXCL12, CXCR4, SDF4 | ITGA4 7/4885ITGB7 16/4885PPARA 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.